Literature DB >> 30778717

Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling.

Tian-Ying Jia1, Jun-Feng Xiong2,3, Xiao-Yang Li1, Wen Yu1, Zhi-Yong Xu1, Xu-Wei Cai1, Jing-Chen Ma2, Ya-Cheng Ren2, Rasmus Larsson2, Jie Zhang4, Jun Zhao5,6,7, Xiao-Long Fu8.   

Abstract

OBJECTIVES: The tyrosine kinase inhibitor (TKI)-sensitive mutations of the epidermal growth factor receptor (EGFR) gene is essential in the treatment of lung adenocarcinoma. To overcome the difficulty of EGFR gene test in situations where surgery and biopsy samples are too risky to obtain, we tried a noninvasive imaging method using radiomics features and random forest models.
METHODS: Five hundred three lung adenocarcinoma patients who received surgery-based treatment were included in this study. The diagnosis and EGFR gene test were based on resections. TKI-sensitive mutations were found in 60.8% of the patients. CT scans before any invasive operation were gathered and analyzed to extract quantitative radiomics features and build random forest classifiers to identify EGFR mutants from wild types. Clinical features (sex and smoking history) were added to the image-based model. The model was trained on a set of 345 patients and validated on an independent test group (n = 158) using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity.
RESULTS: The performance of the random forest model with 94 radiomics features reached an AUC of 0.802. Its AUC was further improved to 0.828 by adding sex and smoking history. The sensitivity and specificity are 60.6% and 85.1% at the best diagnostic decision point.
CONCLUSION: Our results showed that radiomics could not only reflect the genetic differences among tumors but also have diagnostic value and the potential to be a diagnostic tool. KEY POINTS: • Radiomics provides a potential noninvasive method for the prediction of EGFR mutation status. • In situations where surgeries and biopsy are not available, CT image-based radiomics models could help to make treatment decisions. • The accuracy, sensitivity, and specificity still need to be improved before the image-based EGFR identifier could be used in clinics.

Entities:  

Keywords:  Epidermal growth factor receptor (EGFR); Non-small cell lung cancer (NSCLC); Radiomics; Random forest

Mesh:

Substances:

Year:  2019        PMID: 30778717     DOI: 10.1007/s00330-019-06024-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  11 in total

1.  Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Qian Li; Alberto L Garcia; Olya Stringfield; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2016-02-16       Impact factor: 4.785

2.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.

Authors:  Stefania Rizzo; Francesco Petrella; Valentina Buscarino; Federica De Maria; Sara Raimondi; Massimo Barberis; Caterina Fumagalli; Gianluca Spitaleri; Cristiano Rampinelli; Filippo De Marinis; Lorenzo Spaggiari; Massimo Bellomi
Journal:  Eur Radiol       Date:  2015-05-09       Impact factor: 5.315

3.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

4.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

5.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

6.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

Review 7.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Cancer Sci       Date:  2007-09-20       Impact factor: 6.716

8.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.

Authors:  Hugo J W L Aerts; Emmanuel Rios Velazquez; Ralph T H Leijenaar; Chintan Parmar; Patrick Grossmann; Sara Carvalho; Sara Cavalho; Johan Bussink; René Monshouwer; Benjamin Haibe-Kains; Derek Rietveld; Frank Hoebers; Michelle M Rietbergen; C René Leemans; Andre Dekker; John Quackenbush; Robert J Gillies; Philippe Lambin
Journal:  Nat Commun       Date:  2014-06-03       Impact factor: 14.919

9.  Reproducibility of radiomics for deciphering tumor phenotype with imaging.

Authors:  Binsheng Zhao; Yongqiang Tan; Wei-Yann Tsai; Jing Qi; Chuanmiao Xie; Lin Lu; Lawrence H Schwartz
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

10.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105

View more
  40 in total

1.  Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer.

Authors:  Yinjun Dong; Zekun Jiang; Chaowei Li; Shuai Dong; Shengdong Zhang; Yunhong Lv; Fenghao Sun; Shuguang Liu
Journal:  Quant Imaging Med Surg       Date:  2022-05

2.  Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Authors:  Guojin Zhang; Junlin Zhou; Yuntai Cao; Jing Zhang; Zhiyong Zhao; Wenjuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

Review 3.  Radiomics in stratification of pancreatic cystic lesions: Machine learning in action.

Authors:  Vipin Dalal; Joseph Carmicheal; Amaninder Dhaliwal; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Cancer Lett       Date:  2019-10-17       Impact factor: 8.679

4.  A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD).

Authors:  Ying Zhu; Yu-Biao Guo; Di Xu; Jing Zhang; Zhen-Guo Liu; Xi Wu; Xiao-Yu Yang; Dan-Dan Chang; Min Xu; Jing Yan; Zun-Fu Ke; Shi-Ting Feng; Yang-Li Liu
Journal:  Ann Transl Med       Date:  2021-04

5.  Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors.

Authors:  Erica L Carpenter; Despina Kontos; Bardia Yousefi; Michael J LaRiviere; Eric A Cohen; Thomas H Buckingham; Stephanie S Yee; Taylor A Black; Austin L Chien; Peter Noël; Wei-Ting Hwang; Sharyn I Katz; Charu Aggarwal; Jeffrey C Thompson
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 6.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

7.  Implementation strategy of a CNN model affects the performance of CT assessment of EGFR mutation status in lung cancer patients.

Authors:  Junfeng Xiong; Xiaoyang Li; Lin Lu; Schwartz H Lawrence; Xiaolong Fu; Jun Zhao; Binsheng Zhao
Journal:  IEEE Access       Date:  2019-05-13       Impact factor: 3.367

8.  Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma.

Authors:  Yuze Wang; Qi Wan; Xiaoying Xia; Jianfeng Hu; Yuting Liao; Peng Wang; Yu Peng; Hongyan Liu; Xinchun Li
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

9.  Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.

Authors:  Bin Yang; Li Zhou; Jing Zhong; Tangfeng Lv; Ang Li; Lu Ma; Jian Zhong; Saisai Yin; Litang Huang; Changsheng Zhou; Xinyu Li; Ying Qian Ge; Xinwei Tao; Longjiang Zhang; Yong Son; Guangming Lu
Journal:  Respir Res       Date:  2021-06-28

10.  A predictive model for pain response following radiotherapy for treatment of spinal metastases.

Authors:  Kohei Wakabayashi; Yutaro Koide; Takahiro Aoyama; Hidetoshi Shimizu; Risei Miyauchi; Hiroshi Tanaka; Hiroyuki Tachibana; Katsumasa Nakamura; Takeshi Kodaira
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.